In-silico identification of potential inhibitors targeting the DNA binding domain of estrogen receptor α for the treatment of hormone therapy-resistant breast cancer

References

• Ariazi, E. A., Ariazi, J. L., Cordera, F., & Jordan, V. C. (2006). Estrogen Receptors as Therapeutic Targets in Breast Cancer. Current Topics in Medicinal Chemistry, 6 (3), 181–202.
   PubMed Web of Science ®Google Scholar
• Bowers, K. J., Chow, D. E., Xu, H., Dror, R. O., Eastwood, M. P., Gregersen, B. A., & Klepeis, J. L. (2006). Scalable Algorithms for Molecular Dynamics Simulations on Commodity Clusters [Paper presentation]. SC ’06: Proceedings of the 2006 ACM/IEEE Conference on Supercomputing, In, 43–43. https://doi.org/https://doi.org/10.1109/SC.2006.54
   Google Scholar
• Clark, G. M., Osborne, C. K., & McGuire, W. L. (1984). Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. Journal of Clinical Oncology : official Journal of the American Society of Clinical Oncology, 2 (10), 1102–1109. https://doi.org/https://doi.org/10.1200/JCO.1984.2.10.1102
   PubMed Web of Science ®Google Scholar
• Deng, Z., Chuaqui, C., & Singh, J. (2004). Structural interaction fingerprint (SIFt): A novel method for analyzing three-dimensional protein-ligand binding interactions. Journal of Medicinal Chemistry, 47 (2), 337–344. https://doi.org/https://doi.org/10.1021/jm030331x
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). (2015). Aromatase Inhibitors versus Tamoxifen in Early Breast Cancer: Patient-Level Meta-Analysis of the Randomised Trials. Lancet (London, England), 386, 1341–1352. https://doi.org/https://doi.org/10.1016/S0140-6736(15)61074-1
   Google Scholar
• Friesner, R. A., Murphy, R. B., Repasky, M. P., Frye, L. L., Greenwood, J. R., Halgren, T. A., Sanschagrin, P. C., & Mainz, D. T. (2006). Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. Journal of Medicinal Chemistry, 49 (21), 6177–6196. https://doi.org/https://doi.org/10.1021/jm051256o
   PubMed Web of Science ®Google Scholar
• Germain, P., Staels, B., Dacquet, C., Spedding, M., & Laudet, V. (2006). Overview of nomenclature of nuclear receptors. Pharmacological Reviews, 58 (4), 685–704. https://doi.org/https://doi.org/10.1124/pr.58.4.2
   PubMed Web of Science ®Google Scholar
• Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005). Exploiting the PI3K/AKT pathway for cancer drug discovery. Nature Reviews. Drug Discovery, 4 (12), 988–1004. https://doi.org/https://doi.org/10.1038/nrd1902
   PubMed Web of Science ®Google Scholar
• Jakacka, M., Ito, M., Weiss, J., Chien, P. Y., Gehm, B. D., & Jameson, J. L. (2001). Estrogen receptor binding to DNA is not required for its activity through the nonclassical AP1 pathway. The Journal of Biological Chemistry, 276 (17), 13615–13621. https://doi.org/https://doi.org/10.1074/jbc.M008384200
   PubMed Web of Science ®Google Scholar
• Jeselsohn, R., Yelensky, R., Buchwalter, G., Frampton, G., Meric-Bernstam, F., Gonzalez-Angulo, A. M., Ferrer-Lozano, J., Perez-Fidalgo, J. A., Cristofanilli, M., Gómez, H., Arteaga, C. L., Giltnane, J., Balko, J. M., Cronin, M. T., Jarosz, M., Sun, J., Hawryluk, M., Lipson, D., Otto, G., … Miller, V. A. (2014). Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 20 (7), 1757–1767. https://doi.org/https://doi.org/10.1158/1078-0432.CCR-13-2332
   PubMed Web of Science ®Google Scholar
• Keeton, E. K., & Brown, M. (2005). Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT. Molecular Endocrinology (Baltimore, Md.), 19 (6), 1543–1554. https://doi.org/https://doi.org/10.1210/me.2004-0395
   PubMedGoogle Scholar
• Kumar, V., & Chambon, P. (1988). The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell, 55 (1), 145–156. https://doi.org/https://doi.org/10.1016/0092-8674(88)90017-7
   PubMed Web of Science ®Google Scholar
• Kumar, R., Zakharov, M. N., Khan, S. H., Miki, R., Jang, H., Toraldo, G., Singh, R., Bhasin, S., & Jasuja, R. (2011). The dynamic structure of the estrogen receptor. Journal of Amino Acids, 2011, 812540. https://doi.org/https://doi.org/10.4061/2011/812540
   PubMedGoogle Scholar
• Lavinsky, R. M., Jepsen, K., Heinzel, T., Torchia, J., Mullen, T. M., Schiff, R., Del-Rio, A. L., Ricote, M., Ngo, S., Gemsch, J., Hilsenbeck, S. G., Osborne, C. K., Glass, C. K., Rosenfeld, M. G., & Rose, D. W. (1998). Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proceedings of the National Academy of Sciences of the United States of America, 95 (6), 2920–2925. https://doi.org/https://doi.org/10.1073/pnas.95.6.2920
   PubMed Web of Science ®Google Scholar
• Madhavi, G., Adzhigirey, M., Day, T., Annabhimoju, R., & Sherman, W. (2013). Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. Journal of computer-aided molecular design, 27 (3), 221–234. https://doi.org/https://doi.org/10.1007/s10822-013-9644-8
   PubMed Web of Science ®Google Scholar
• Mantsyzov, A. B., Bouvier, G., Evrard-Todeschi, N., & Bertho, G. (2012). Contact-based ligand-clustering approach for the identification of active compounds in virtual screening. Advances and Applications in Bioinformatics and Chemistry : AABC, 5, 61–79.https://doi.org/https://doi.org/10.2147/AABC.S30881.
   PubMedGoogle Scholar
• Merenbakh-Lamin, K., Ben-Baruch, N., Yeheskel, A., Dvir, A., Soussan-Gutman, L., Jeselsohn, R., Yelensky, R., Brown, M., Miller, V. A., Sarid, D., Rizel, S., Klein, B., Rubinek, T., & Wolf, I. (2013). D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer. Cancer Research, 73 (23), 6856–6864. https://doi.org/https://doi.org/10.1158/0008-5472.CAN-13-1197
   PubMed Web of Science ®Google Scholar
• Nardone, A., De Angelis, C., Trivedi, M. V., Osborne, C. K., & Schiff, R. (2015). The changing role of er in endocrine resistance. Breast (Edinburgh, Scotland)), 24 Suppl 2 (Suppl 2):S60–S66. https://doi.org/https://doi.org/10.1016/j.breast.2015.07.015
   PubMedGoogle Scholar
• Ng, H. W., Perkins, R., Tong, W., & Hong, H. (2014). Versatility or promiscuity: The estrogen receptors, control of ligand selectivity and an update on subtype selective ligands. International Journal of Environmental Research and Public Health, 11 (9), 8709–8742. https://doi.org/https://doi.org/10.3390/ijerph110908709
   PubMed Web of Science ®Google Scholar
• Osborne, C. K. (1998). Tamoxifen in the treatment of breast cancer. The New England Journal of Medicine, 339 (22), 1609–1618. https://doi.org/https://doi.org/10.1056/NEJM199811263392207
   PubMed Web of Science ®Google Scholar
• Osborne, C. K., Bardou, V., Hopp, T. A., Chamness, G. C., Hilsenbeck, S. G., Fuqua, S. A. W., Wong, j., Craig Allred, j. W. D., Clark, G. M. & Schiff, R., (2003). Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/Neu in tamoxifen resistance in breast cancer. Journal of the National Cancer Institute, 95 (5), 353–361. https://doi.org/https://doi.org/10.1093/jnci/95.5.353
   PubMedGoogle Scholar
• QikProp, S. (2020). Schrödinger Release 2020-2: QikProp. Schrödinger, LLC.
   Google Scholar
• Robertson, J. F. R., Osborne, C. K., Howell, A., Jones, S. E., Mauriac, L., Ellis, M., Kleeberg, U. R., Come, S. E., Vergote, I., Gertler, S., Buzdar, A., Webster, A., & Morris, C. (2003). Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: A prospective combined analysis of two multicenter trials. Cancer, 98 (2), 229–238. https://doi.org/https://doi.org/10.1002/cncr.11468
   PubMed Web of Science ®Google Scholar
• Robinson, D. R., Wu, Y.-M., Vats, P., Su, F., Lonigro, R. J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., Gursky, A., Siddiqui, J., Tomlins, S. A., Roychowdhury, S., Pienta, K. J., Kim, S. Y., Roberts, J. S., Rae, J. M., Van Poznak, C. H., … Chinnaiyan, A. M. (2013). Activating ESR1 Mutations in Hormone-Resistant Metastatic Breast Cancer. Nature Genetics, 45 (12), 1446–1451. https://doi.org/https://doi.org/10.1038/ng.2823
   PubMed Web of Science ®Google Scholar
• Schwabe, J. W., Chapman, L., Finch, J. T., & Rhodes, D. (1993). The crystal structure of the estrogen receptor DNA-binding domain bound to DNA: How receptors discriminate between their response elements. Cell, 75 (3), 567–578. https://doi.org/https://doi.org/10.1016/0092-8674(93)90390-C
   PubMed Web of Science ®Google Scholar
• Shou, J., Massarweh, S., Osborne, C. K., Wakeling, A. E., Ali, S., Weiss, H., & Schiff, R. (2004). Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/Neu cross-talk in ER/HER2-positive breast cancer. Journal of the National Cancer Institute, 96 (12), 926–935. https://doi.org/https://doi.org/10.1093/jnci/djh166
   PubMedGoogle Scholar
• Tervonen, T. A., Belitškin, D., Pant, S. M., Englund, J. I., Marques, E., Ala-Hongisto, H., Nevalaita, L., Sihto, H., Heikkilä, P., Leidenius, M., Hewitson, K., Ramachandra, M., Moilanen, A., Joensuu, H., Kovanen, P. E., Poso, A., & Klefström, J. (2016). Deregulated hepsin protease activity confers oncogenicity by concomitantly augmenting HGF/MET signalling and disrupting epithelial cohesion. Oncogene, 35 (14), 1832–1846. https://doi.org/https://doi.org/10.1038/onc.2015.248
   PubMed Web of Science ®Google Scholar
• Toy, W., Shen, Y., Won, H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K., Fanning, S., King, T. A., Hudis, C., Chen, D., Taran, T., Hortobagyi, G., Greene, G., Berger, M., Baselga, J., & Chandarlapaty, S. (2013). ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nature Genetics, 45 (12), 1439–1445. https://doi.org/https://doi.org/10.1038/ng.2822
   PubMed Web of Science ®Google Scholar
• van de Waterbeemd, H., & Gifford, E. (2003). ADMET in silico modelling: Towards prediction paradise? Nature Reviews. Drug Discovery, 2 (3), 192–204. https://doi.org/https://doi.org/10.1038/nrd1032
   PubMed Web of Science ®Google Scholar
• Weatherman, R. V., Fletterick, R. J., & Scanlan, T. S. (1999). Nuclear-receptor ligands and ligand-binding domains. Annual Review of Biochemistry, 68, 559–581. https://doi.org/https://doi.org/10.1146/annurev.biochem.68.1.559
   PubMed Web of Science ®Google Scholar